• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比较低分子量肝素与普通肝素在减轻深静脉血栓形成患者下肢周长方面的有效性。

To Compare the Effectiveness of Low-Molecular-Weight Heparin and Unfractionated Heparin in Reducing Lower Limb Girth in Deep Vein Thrombosis.

作者信息

Ullalkar Neha, M Vedanth, Pn Sreeramulu, Vaibhavi D, Ca Shashirekha

机构信息

General Surgery, Sri Devaraj Urs Medical College, Kolar, IND.

Surgery, Sri Devaraj Urs Medical College, Kolar, IND.

出版信息

Cureus. 2024 May 1;16(5):e59449. doi: 10.7759/cureus.59449. eCollection 2024 May.

DOI:10.7759/cureus.59449
PMID:38827007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11141321/
Abstract

INTRODUCTION

Treating deep vein thrombosis (DVT) using a once-daily dose of enoxaparin offers greater convenience and the possibility of home-based care for certain patients, as opposed to a continuous infusion of unfractionated heparin (UFH). The study aimed to determine the most cost-effective thromboprophylaxis between low-molecular-weight heparin (LMWH) and UFH for hospitalized patients.

MATERIALS AND METHODS

After obtaining clearance from the institutional ethical committee, the study was conducted in the Department of General Surgery, Sri Devaraj Urs Medical College, over a period of six months. Informed consent was obtained from all 46 patients included in this study. The participants were divided into two groups: group A received LMWH and group B received UFH.

RESULTS

The mean age in group A was 59.8 + 10.6 years and in group B was 54.9 + 12.3 years. There was no significant difference in the girth of the lower limb between the groups during the follow-up period (p > 0.05). In group A, there was a highly significant reduction in lower limb girth from day one to day five (p < 0.0001), day five to day 10 (p < 0.0001), and day one to day 10 (p < 0.0001). In group B, there was no significant reduction from day one to day five (p = 0.06), but there was a significant reduction from day five to day 10 (p = 0.001) and day one to day 10 (p = 0.001).

CONCLUSION

Treatment with LMWH as an anticoagulant significantly reduced the lower extremity girth and thrombus thickness in cases of DVT when compared to UFH.

摘要

引言

与持续输注普通肝素（UFH）相比，每日一次剂量的依诺肝素治疗深静脉血栓形成（DVT）为某些患者提供了更大的便利性以及居家护理的可能性。该研究旨在确定住院患者中低分子量肝素（LMWH）和UFH之间最具成本效益的血栓预防措施。

材料与方法

在获得机构伦理委员会批准后，该研究在斯里德瓦拉杰·乌尔什医学院普通外科进行，为期六个月。本研究纳入的46例患者均获得了知情同意。参与者分为两组：A组接受LMWH，B组接受UFH。

结果

A组的平均年龄为59.8±10.6岁，B组为54.9±12.3岁。随访期间两组下肢周长无显著差异（p>0.05）。在A组中，从第1天到第5天、第5天到第10天以及第1天到第10天，下肢周长均有极显著降低（p<0.0001）。在B组中，从第1天到第5天无显著降低（p = 0.06），但从第5天到第10天以及第1天到第10天有显著降低（p = 0.001）。

结论

与UFH相比，LMWH作为抗凝剂治疗可显著降低DVT患者的下肢周长和血栓厚度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb8d/11141321/cd180584dd42/cureus-0016-00000059449-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb8d/11141321/cd180584dd42/cureus-0016-00000059449-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb8d/11141321/cd180584dd42/cureus-0016-00000059449-i01.jpg

相似文献

1
To Compare the Effectiveness of Low-Molecular-Weight Heparin and Unfractionated Heparin in Reducing Lower Limb Girth in Deep Vein Thrombosis.比较低分子量肝素与普通肝素在减轻深静脉血栓形成患者下肢周长方面的有效性。
Cureus. 2024 May 1;16(5):e59449. doi: 10.7759/cureus.59449. eCollection 2024 May.
2
Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.多中心、三臂、随机对照试验研究甲泼尼龙和普通肝素在 SARS-CoV-2 感染肺炎危重症机械通气患者中的应用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Aug 17;21(1):724. doi: 10.1186/s13063-020-04645-z.
3
A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.低分子量肝素与双氢麦角胺固定剂量组合对比调整剂量普通肝素预防全髋关节置换术后深静脉血栓形成的研究
Thromb Haemost. 1996 Feb;75(2):246-50.
4
Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.孕期及产后早期静脉血栓栓塞性疾病的预防
Cochrane Database Syst Rev. 2014 Feb 11(2):CD001689. doi: 10.1002/14651858.CD001689.pub3.
5
Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.与静脉注射普通肝素相比，静脉注射或皮下注射低分子量肝素治疗深静脉血栓形成的疗效。舍托肝素研究组。
Int Angiol. 1998 Sep;17(3):135-45.
6
Home versus in-patient treatment for deep vein thrombosis.深静脉血栓形成的家庭治疗与住院治疗对比
Cochrane Database Syst Rev. 2018 Jan 9;1(1):CD003076. doi: 10.1002/14651858.CD003076.pub3.
7
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.一项关于每日一次剂量的依诺肝素与普通肝素治疗下肢近端深静脉血栓形成的疗效和安全性的开放标签对照研究。
Thromb Res. 2004;114(3):149-53. doi: 10.1016/j.thromres.2004.05.009.
8
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.普通肝素与低分子量肝素用于预防术后患者肝素诱导的血小板减少症的比较
Cochrane Database Syst Rev. 2012 Sep 12(9):CD007557. doi: 10.1002/14651858.CD007557.pub2.
9
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.随机对照试验比较高剂量与低剂量低分子肝素在需要侵入性机械通气的严重 COVID-19 肺炎和凝血病住院患者中的疗效和安全性 (COVID-19 HD)：研究方案的结构化总结。
Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
10
Comparison of unfractionated heparin vs low molecular weight heparin in the treatment of acute deep vein thrombosis.普通肝素与低分子量肝素治疗急性深静脉血栓形成的比较。
J Coll Physicians Surg Pak. 2005 Oct;15(10):601-4.

本文引用的文献

1
Morphologic change in deep venous thrombosis in the lower extremity after therapeutic anticoagulation.治疗性抗凝后下肢深静脉血栓形成的形态学变化
Thromb J. 2021 Dec 14;19(1):99. doi: 10.1186/s12959-021-00352-0.
2
Updated recommendations for the treatment of venous thromboembolism.静脉血栓栓塞症治疗的更新建议。
Blood Res. 2021 Mar 31;56(1):6-16. doi: 10.5045/br.2021.2020083.
3
Anticoagulation for perioperative thromboprophylaxis in people with cancer.癌症患者围手术期血栓预防的抗凝治疗
Cochrane Database Syst Rev. 2018 Jul 11;7(7):CD009447. doi: 10.1002/14651858.CD009447.pub3.
4
Epidemiology of the post-thrombotic syndrome.血栓后综合征的流行病学。
Thromb Res. 2018 Apr;164:100-109. doi: 10.1016/j.thromres.2017.07.026. Epub 2017 Jul 24.
5
Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.急性肺栓塞后慢性血栓栓塞性肺动脉高压的发生率：已发表文献的当代观点。
Eur Respir J. 2017 Feb 23;49(2). doi: 10.1183/13993003.01792-2016. Print 2017 Feb.
6
The epidemiology of venous thromboembolism.静脉血栓栓塞症的流行病学
J Thromb Thrombolysis. 2016 Jan;41(1):3-14. doi: 10.1007/s11239-015-1311-6.
7
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. Wells 评分和 D-二聚体在孤立性远端下肢深静脉血栓形成诊断中的应用。
J Thromb Haemost. 2012 Nov;10(11):2264-9. doi: 10.1111/j.1538-7836.2012.04895.x.
8
Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study.深静脉血栓形成和肺栓塞后的患者预后：伍斯特静脉血栓栓塞研究
Arch Intern Med. 2008 Feb 25;168(4):425-30. doi: 10.1001/archinternmed.2007.69.
9
Venous thromboembolic disease and cancer.静脉血栓栓塞性疾病与癌症
Postgrad Med J. 2006 Oct;82(972):642-8. doi: 10.1136/pgmj.2006.046987.
10
Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality.治疗后残留血栓会增加复发性深静脉血栓形成和死亡的风险。
J Thromb Haemost. 2006 Sep;4(9):1919-24. doi: 10.1111/j.1538-7836.2006.02120.x.